Barclays analyst Matt Miksic maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on May 3 and set a price target of

By Denny Jacob Tandem Diabetes Care shares rose 17% in premarket trading after it bumped up its adjusted sales outlook for 2024. Shares were trading

Tandem grew Q1 sales 13% year over year on a 9% increase in units shipped. Curiously, Tandem showed its greatest growth -- 67% -- in units sold outside the U.S., while U.S. shipments declined 12%. That translated into only a 1% decline in U.S. revenue, however, while ex-U.S. sales surged 63%.